Generated by AI
Minerva Neurosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for central nervous system disorders. Its current pipeline centers on roluperidone, a product candidate being studied for the treatment of negative symptoms in schizophrenia, and other CNS-related programs such as seltorexant. The company’s work is concentrated on advancing proprietary medicines through clinical development and regulatory pathways, with an emphasis on conditions where treatment options remain limited. Minerva Neurosciences serves a specialized role in the biopharmaceutical market by targeting neuropsychiatric and neurological diseases that affect patients, clinicians, and healthcare systems worldwide. Headquartered in Burlington, Massachusetts, Minerva Neurosciences operates as a research-driven company whose primary business is the development and commercialization of product candidates for complex brain and nervous system disorders.
Website1500 District Avenue
Burlington, MA, 01803
United States
The latest articles about NERV.
BURLINGTON, Mass., Oct. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system disorders, today announced that it will host an in-person and virtual event in New York on Thursday, November 12, 2026, at 10:00 AM ET featuring several key opinion leaders and company management focused on the opportunity for roluperidone in treating the negative symptoms of schizophren
Summary of Mar 9's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Summary of Mar 9's posts. Generated by AI.
Investors talking about NERV also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.